Development of Medical Countermeasures for Biodefense and Emerging Diseases

Information

• Research Project
• 9785326

• ApplicationId

  9785326

• Core Project Number

• Full Project Number

  272201300017C-22-0-1

• Serial Number

• FOA Number

• Sub Project Id

• Project Start Date

  8/1/2016 - 8 years ago

• Project End Date

  9/30/2022 - 2 years ago

• Program Officer Name

• Budget Start Date

  -

• Budget End Date

  -

• Fiscal Year

  2018

• Support Year

• Suffix

• Award Notice Date

  -

Organizations

• BIOCRYST PHARMACEUTICALS, INC

This contract supports the advanced development of promising therapeutic candidates with broad spectrum activity. The research and development activities to be supported will allow candidate therapeutic products to progress through the product development pipeline, and includes preclinical and non-clinical activities, as well as IND development activities.

IC Name

• Activity

  N01

• Administering IC

  AI

• Application Type

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  3557707

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

• Ed Inst. Type

• Funding ICs

  NIAID:3557707\

• Funding Mechanism

  Non SBIR/STTR Contracts

• Study Section

• Study Section Name

• Organization Name

  BIOCRYST PHARMACEUTICALS, INC.

• Organization Department

• Organization DUNS

  618194609

• Organization City

  DURHAM

• Organization State

  NC

• Organization Country

  UNITED STATES

• Organization Zip Code

  277030087

• Organization District

  UNITED STATES